Clinical trials recruiting in Quimper, France

Phase breakdown

Conditions recruiting in Quimper, France

Recruiting trials in Quimper, France

• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT06417814 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
  NCT04916613 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
  NCT06487078 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
  NCT05899608 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Dat'Aids Prevention
  NCT03795376 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
  NCT06393816 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase
  NCT06441773 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement?
  NCT06643845 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female)
• Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
  NCT07566195 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response
  NCT06906328 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female)
• PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
  NCT06646471 · Phase: Phase 4 · Ages: 70 Years and older · Sex: All (male and female)
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
  NCT06078384 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
  NCT06552234 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Quality of Care in French HIV Infected Patients
  NCT02898987 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• RETRO-PROSPECTIVE POSTMARKET CLINICAL STUDY FOR FX SHOULDER SOLUTIONS SHOULDER SYSTEMS
  NCT07558590 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
  NCT05758831 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
  NCT06758401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Quimper, France?

25 recruiting trials have at least one study site in Quimper, France.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.